$PLUS

Marion Elaine D sold $690K of PLUS (indirect holdings)

Marion Elaine D (CHIEF FINANCIAL OFFICER) sold 7,182 indirectly-held shares of EPLUS INC (PLUS) at an average of $96.11 ($95.12–$97.40, $0.69M total) across 4 trades over 2026-08-03 to 2026-08-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Marion Elaine D
Published Aug 5, 2026, 8:26 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 8:41 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PLUS
Neutral
high confidence
Mentioned
$PLUS
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PLUSNeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on insider selling activity and the execution price range, but it does not introduce new operational, financial, regulatory, or deal information.

02

Market read

For traders, this is mainly a sentiment check on insider activity; the 10b5-1 framing reduces interpretive weight.

03

What to watch

Traders may over-weight insider sales; the key incremental detail here is only the sale size, timing, and price range, not any change in guidance or strategy.

Relevance 4/10Novelty 3/10Timing: filed Aug 5, covering sales executed Aug 3 to Aug 4

Background

The article is an SEC Form 4 insider transaction disclosure for EPLUS Inc (PLUS), reported by the CFO, with sales executed over Aug 3 to Aug 4 under a 10b5-1 plan.

Company-level read

Ticker impact

$PLUSNeutralHigh confidence
Context

EPLUS CFO Marion Elaine D sold about $690K of PLUS shares via a 10b5-1 plan across four trades at roughly $95.12 to $97.40.

Expected impact

Likely limited, with any impact confined to short-term sentiment rather than fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan; it discloses sale activity and pricing but no new company-specific operating or financial information.

Market effects

Minimal, as this is company-specific insider selling with no sector-wide signal.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may not reflect bearish expectations and could be mechanically scheduled compensation liquidity.

Key entities

  • PLUS

    EPLUS Inc, the issuer of the shares sold by the CFO.

  • Marion Elaine D

    Chief Financial Officer reporting the Form 4 insider sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CDWMedAI 8/10

Q2 Earnings Outperformers: CDW (NASDAQ:CDW) And The Rest Of The IT Distribution & Solutions Stocks

CDW, ePlus, TD SYNNEX, and ScanSource reported Q2 earnings. CDW (-6%) and ePlus (-10.5%) saw stock declines, while ScanSource (+5.5%) rose. TD SYNNEX (-10.5%) reported strong revenue growth but also fell. ePlus reported flat revenue but beat EPS estimates. ScanSource had the largest analyst estimate beat. TD SYNNEX reported $19.57B revenue, up 31% YoY, and beat EPS estimates and guidance.

$PLUSMed

Plus500 increases buybacks as US growth continues

Plus500 said it will increase shareholder returns via buybacks alongside its half-year results. The company reported double-digit revenue growth year over year and Ebitda up 1% to $188mn. It attributed a lower Ebitda margin (45% to 41%) to higher marketing spend to attract new customers, while expanding in US futures.

$PLUSMedAI 8/10

Why ePlus (PLUS) Shares Are Plunging Today

ePlus (NASDAQ: PLUS) shares fell about 5% after the company reported Q2 2026 results. Revenue rose 1.9% year over year to $649.1 million and adjusted EPS was $1.28, both above Wall Street estimates. Despite the beat, investors focused on declining adjusted operating and free cash flow margins and a forecast of about 2% full-year EPS growth. Shares later traded near $92.31.